Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor

18 Nov 2021

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 34801727
DOI: 10.1016/j.ymthe.2021.11.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptorPMID 34801727Read ↗

Chimeric Antigen Receptor T-cell Therapy to Target Hematologic MalignanciesSemantic proximity Read ↗

The therapeutic landscape for cells engineered with chimeric antigen receptorsSemantic proximity Read ↗

Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantationSemantic proximity Read ↗

HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activationSemantic proximity Read ↗

Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor ActivitySemantic proximity Read ↗

Genome-edited allogeneic donor “universal” chimeric antigen receptor T cellsSemantic proximity Read ↗

HLA-G engineering reprograms CAR-T cells with an immune privilegeSemantic proximity Read ↗

Adoptive Cell Therapy—Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen ReceptorsSemantic proximity Read ↗

Chimeric Antigen Receptor T-Cell Therapy: What We Expect SoonSemantic proximity Read ↗

Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challengesSemantic proximity Read ↗

De-novo and acquired resistance to immune checkpoint targetingSemantic proximity Read ↗

Design and Preclinical Development of a Novel In Vivo Chimeric Antigen Receptor (CAR) Product for B-Cell Involved DiseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.